|
Variables
|
Cases
|
IGFBP-1(ng/L)
|
Significance
|
IGF-1(ng/L)
|
Significance
|
IGFBP-1/IGF-1
|
Significance
|
|---|
|
(n)
|
(Mean ± SD)
|
(P)*
|
(Mean ± SD)
|
(P)*
|
>1
|
≤1
|
(P)*
|
|---|
|
Gender
|
|
Male
|
118
|
55.08 ± 41.66
|
0.966
|
88.26 ± 60.75
|
0.018*
|
38
|
80
|
0.202
|
|
Female
|
24
|
55.93 ± 40.05
|
135.98 ± 88.78
|
4
|
20
|
|
Age (y)
|
|
< 46
|
73
|
47.18 ± 36.51
|
0.020*
|
103.65 ± 69.31
|
0.217
|
16
|
57
|
0.016*
|
|
≥ 46
|
69
|
63.85 ± 44.47
|
89.02 ± 66.48
|
28
|
41
|
|
Tumor size
|
|
T1 + T2
|
27
|
47.54 ± 36.71
|
0.260
|
87.09 ± 55.78
|
0.437
|
7
|
20
|
0.528
|
|
T3 + T4
|
115
|
57.01 ± 42.18
|
100.71 ± 74.63
|
37
|
78
|
|
Lymphoid nodal states
|
|
N0-1
|
76
|
51.02 ± 41.80
|
0.156
|
96.69 ± 75.17
|
0.946
|
20
|
56
|
0.197
|
|
N2-3
|
66
|
59.99 ± 40.41
|
99.79 ± 67.59
|
24
|
42
|
|
Clinical Stage
|
|
1 + 2
|
15
|
39.11 ± 37.45
|
0.101
|
99.42 ± 58.73
|
0.853
|
3
|
12
|
0.498
|
|
3 + 4
|
127
|
57.11 ± 41.40
|
97.99 ± 73.02
|
41
|
86
|
|
Local-regional relapse
|
|
Yes
|
16
|
49.59 ± 39.68
|
0.537
|
117.07 ± 88.62
|
0.198
|
4
|
12
|
0.793
|
|
No
|
126
|
55.94 ± 41.55
|
95.76 ± 69.08
|
40
|
86
|
|
Metastasis
|
|
Yes
|
4
|
43.16 ± 41.80
|
0.542
|
58.52 ± 27.71
|
0.263
|
1
|
3
|
0.775
|
|
No
|
138
|
55.96 ± 41.20
|
97.42 ± 68.94
|
43
|
95
|
|
WHO histological classification
|
|
NKUC
|
131
|
57.05 ± 41.94
|
0.044*
|
98.25 ± 73.73
|
0.978
|
44
|
87
|
0.048*
|
|
NKDC
|
11
|
38.18 ± 25.70
|
96.88 ± 36.79
|
0
|
11
|
|
EA
|
|
≤ 1:10
|
53
|
44.34 ± 36.35
|
0.015*
|
104.31 ± 78.59
|
0.431
|
10
|
43
|
0.016*
|
|
> 1:10
|
89
|
61.64 ± 42.79
|
94.51 ± 67.14
|
34
|
55
|
|
VCA
|
|
≤ 1:40
|
14
|
57.45 ± 43.73
|
0.860
|
102.20 ± 50.26
|
0.736
|
2
|
12
|
0.263
|
|
> 1:40
|
128
|
55.39 ± 41.05
|
95.68 ± 70.16
|
42
|
86
|
- *P < 0.05, as determined by Pearson’s Χ
2 test
